"Aseptic Filling Machine Market Industry Trends and Global Forecasts to 2035, by Type of Compatible Primary Container (Vials, Syringes, Cartridges, Ampoules, Capsules, and Other Containers), Scale of ...

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to ...

Dublin, May 27, 2020 (GLOBE NEWSWIRE) -- The "Fill Finish Manufacturing Market by Product (Consumables (Prefilled Syringes (Glass, Plastic), Vial), Instruments ...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Aseptic Filling Machines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...

Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Biologics Fill Finish Services Market: Industry Trends and Global Forecasts to 2035" report has been added to ResearchAndMarkets.com's offering. The ...

New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global ...

Innovative Machinery Added to San Diego and Melbourne Sites Enhances Global Offerings PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global contract development and manufacturing ...

(RTTNews) - ADMA Biologics, Inc. (ADMA) announced FDA Approval for the company's in-house aseptic fill-finish machine, the VanRx SA25. The company said the VanRx approval provides ADMA with internal ...

Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Fill-finish Pharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been ...

Fill and finish operations involve filling and sealing products into final-user containers with sterile procedures. These services are most useful for medical-grade products like cartridges, medicinal ...

The development of genetically engineered drugs is a relatively new endeavor. Insulin, as Humulin® from Eli Lilly & Co. and approved in 1982, was the first genetically engineered biopharmaceutical.